Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nektarios Kostopoulos"'
Autor:
Mireia Uribe-Herranz, Silvia Beghi, Marco Ruella, Kalpana Parvathaneni, Silvano Salaris, Nektarios Kostopoulos, Subin S. George, Stefano Pierini, Elisavet Krimitza, Francesca Costabile, Guido Ghilardi, Kimberly V. Amelsberg, Yong Gu Lee, Raymone Pajarillo, Caroline Markmann, Bevin McGettigan-Croce, Divyansh Agarwal, Noelle Frey, Simon F. Lacey, John Scholler, Khatuna Gabunia, Gary Wu, Elise Chong, David L. Porter, Carl H. June, Stephen J. Schuster, Vijay Bhoj, Andrea Facciabene
Publikováno v:
Molecular Therapy. 31:686-700
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f452ab38962928b51e549d95a9be6f55
https://doi.org/10.1016/j.ymthe.2023.01.012
https://doi.org/10.1016/j.ymthe.2023.01.012
Autor:
Nektarios Kostopoulos, Costanitnos Koumeins, John P. Plastaras, Stephen J. Schuster, Andrea Facciabene
Publikováno v:
Cancer Research. 82:3449-3449
CD19-targeted chimeric antigen receptor (CAR) T cells have transformed the treatment of patients with relapsed or refractory CD19-positive hematologic malignancies. However, a significant subset of these patients either fails to respond or eventually
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2178f4306298d8260bea666bb8a7d1c
https://doi.org/10.1158/1538-7445.am2022-3449
https://doi.org/10.1158/1538-7445.am2022-3449
Autor:
Renzo Perales Linares, Hesham Mohei, Nektaria M. Leli, Silvia Beghi, Nektarios Kostopoulos, Amit Maity, Costantinos Koumenis, Andrea Facciabene
Publikováno v:
Cancer Research. 82:3846-3846
A growing body of evidence supports the role of Parkin as a tumor suppressor involved in a number of cellular processes, including the downregulation of cell cycle and proliferation, migration, invasion, metastasis, mitophagy, and energy metabolic re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc8e77e4858eee9d913b33a7810413ad
https://doi.org/10.1158/1538-7445.am2022-3846
https://doi.org/10.1158/1538-7445.am2022-3846
Autor:
Khatuna Gabunia, Stephen J. Schuster, Noelle V. Frey, David L. Porter, Nektarios Kostopoulos, Simon F. Lacey, Carl H. June, Andrea Facciabene, Raymone Pajarillo, Mireia Uribe-Herranz, Vijay Bhoj, Guido Ghilardi, Kalpana Parvathaneni, Elise A. Chong, John Scholler, Marco Ruella, Silvia Beghi, Yong Gu Gu Lee, Kimberly Amelsberg
Publikováno v:
Blood. 138:163-163
Background: Chimeric Antigen Receptor (CAR) T cell immunotherapy has revolutionized the treatment of B-cell malignancies. However, a significant subset of these patients either fails to respond or eventually relapses. Moreover, in solid cancers, CAR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6205adfbf74d3ccd67a3ac6fa649709
https://doi.org/10.1182/blood-2021-151093
https://doi.org/10.1182/blood-2021-151093